High-intensity focused ultrasound (HIFU) has been proposed as a possible therapy option for several types of tumors that are complicated to treat. HIFU is considered investigational as a therapeutic option; however, there are specific tumors that could be targeted for treatment, contingent on approval for human use in the United States. The ability to provide noninvasive treatment for tumors of the prostate, uterus, and brain is advantageous, and clinical trials that have been conducted abroad are very promising.
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A literature review is provided concerning the scientific studies that have been published involving high-intensity focused ultrasound (HIFU) as a therapeutic treatment for tumors of the prostate, uterus, and brain. This is a revival of earlier work that now focuses on targeted therapy with sonography, but the studies that have been conducted vary in their level of evidence and translation to clinical practice. The review arranges the published studies by levels of evidence and provides a meta-analysis of the potential for using HIFU to treat prostate cancer, fibroids, and glioblastomas. Human studies are needed that provide clear levels of frequency, intensity, temperature, and treatment patterns. The bioeffects of sonography play a huge role in the destruction of these tumors as well as the potential to cause collateral damage in the surrounding healthy tissue. The hope is that with continued research, a fusion of technology with HIFU can provide patients with a noninvasive, nonionizing therapy for these lesions.
from the late 1970s to the early 1990s, was 25% to 114%. Canada has also seen an increase in prostate cancer incidence during these same time periods, with a jump from 24% to 55%. 1 Although differences in genetics and environmental factors may be the key to these increases in incidence, finding a noninvasive technique for treating these tumors is paramount.
Leiomyomata (fibroid) are fibroconnective tissue tumors found in the uterus, which have a low tendency toward malignancy. These tumors have a 50% incidence in women who are 50 years of age and older. 2 Most of these benign tumors are located in the intramural layer, with less than 10% lying below the submucosa. Most patients (85%) are found to have more than one leiomyomata. Due to a direct relationship between incidence and increasing age, a noninvasive technique for removing these benign tumors would be advantageous.
Glioblastomas are metastatic brain tumors arising from the lung, which form a central mass and can migrate to the periphery. 3 Length of survival from these tumor invasions has been linked to not only the removal of the host tumor but also its tentacles. Magnetic resonance imaging (MRI) has demonstrated that these tumor cells migrate more than 2 cm from the host tumor. 4 The incidence of glioblastomas in the United States, from 1970 to this century, has remained stationary at 3.23% to 3.69% in men and 2.08% to 2.36% in women. Glioblastomas are associated with increasing age and have a mean age at incidence of 54 years. 5 Noninvasive methods for destroying the host tumor and invasive debris would be a tremendous asset in survival and quality of life for these patients.
In the future, HIFU could be a therapeutic option to treat these tumors. This advanced technology would destroy the tumor centrally and any migrating cells without compromising the host organ and intervening tissues between the transducer and the mass.
Technique/Physics
HIFU makes use of the bioeffects that occur with the insonation of human tissue with HIFU waves. The basic effects are the change of sonographic energy into heat and cavitation. 6 Heat is caused by the friction that results from vibrating tissues interacting over time. Cavitation is the result of gas bubbles developing within tissues due to prolonged exposure to high-intensity sonographic energy. The bursting of these bubbles within the tissue planes causes significant cellular damage; this is referred to as transient caviation. 6 HIFU differs from diagnostic sonography exposure by the intent to maximize these biological effects to cause destruction of tumor cells and tissue planes.
Innovations in HIFU transducer construction have allowed for an improvement in the design of transducer arrays, acoustic materials, and delivery systems. Advancements in both the delivery and construction of HIFU have improved beam control, treatment times, and the ability to control beam distortion. An example of innovation and variability among systems to administer HIFU is a choice between treating tumors with a single transducer that is mechanically moved or a phased-array transducer that is electronically steered.
The single-transducer approach uses frequencies between 0.5 and 10 MHz, with the average around 1.5 MHz. 7 With focusing (often with an aluminum lens), the intensity varies per procedure between 10 3 and 10 4 W/cm 2 , over a time period of 1 to 30 seconds.
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A phased-array transducer designed for HIFU typically is constructed of 1 to 3 lead zirconate titanate (PZT) composite elements that provide high acoustic power over a higher bandwidth. 7 These transducers typically have at least 500 elements and are arranged to provide more focused applications. 7 One pitfall to the use of these transducers has been the increase in grating lobes. This becomes most noticeable when the focus is electronically moved off the central axis of treatment. Grating lobes have been investigated to determine what effect they might have on weaning the intensity from the focal point of the beam. 8 Depending on the application of HIFU and the area of the body, many of the studies reviewed have built transducers and delivery systems that are unique to their research. A comparison between systems becomes difficult due to the variability of many of these experimental configurations.
HIFU delivery does have the commonality of maximizing biological effects, which are governed by certain physical properties, to provide direct treatment. The fundamental concepts on which sonographic procedures are based include the transmission frequency and the spatial peak temporal average (SPTA) intensity. The transducer itself has a specific range of output capability. An increase in frequency and/or output will have a direct effect on the temperature of the local tissue. As expected, heating increases as intensity and frequency are increased. It is equally important to note that, because of the attenuation, tissue located at a greater depth from the surface will heat to a lesser degree. This occurs because of the tissue's ability to absorb energy and the tendency for this energy to diffuse to a lower strength as it travels farther away from the source. 9 The intensity of the beam is also governed by the density of the tissue that it is traveling through. For example, bone absorbs more energy than soft tissues, which is critical when determining the dosage required for therapeutic effects. These differences are accounted for in the mathematical index calculations for the soft tissue thermal index (TIS) and bone thermal index (TIB). These indices are the foundation for the ALARA principle, or as low as reasonably achievable, used in diagnostic sonographic practice. Research thus far has concluded that temperature increases exceeding 2°C will damage tissue. This threshold is achieved at an energy level of 100 mW/cm 2 . 10 Animal models have been used to explore the vascular diffusion of heat across tissue planes. These kinds of experiments administer HIFU with continuous-wave or gradient pulses. 11, 12 An important factor is the diffusion of heat due to the vascular flow that naturally occurs throughout the tissue after a pulsed dose of high-frequency ultrasound. As time and vascular flow increases, heat is diffused (see Fig. 1 ).
In addition to thermal effects in tissue caused by the sonographic process, it is vital to recognize the related pressure effects. A sound wave creates pressure changes as it propagates through a medium; in this case, the medium is tissue. Depending on the intensity and frequency at which the transducer is operating, the amplitude of the sound wave is directly related to increasing pressure against the tissue. Because the tissues are largely composed of fluids, cavitation can occur as the sound wave propagates. As the amplitude/pressure of the sound wave increases, transient cavitation can occur and cause rather significant destruction of cells and, ultimately, the tissue. As with the thermal aspect of sonography (thermal index [TI]), there is a mechanic index (MI) used to measure the threshold at which the pressure becomes destructive, which is still under research.
The importance of understanding the physics involved with diagnostic sonography is that research in HIFU seeks to go far beyond the threshold levels of safety in the realm of diagnostics. As this research continues, a protocol will be developed to control the destruction of tissues, thereby producing a less invasive treatment for tumors.
Literature Review
HIFU has been explored as a potentially effective nonionizing therapy for a variety of cancers. The following literature review is presented using an evidenced-based practice strategy with studies sorted from lowest to highest level of impact. This literature review focuses on the use of HIFU to treat cancer in the following sites: prostate, uterus, and brain. The articles selected were located after an online literature search of PubMed and Google Scholar, using the keyword HIFU. Articles were chosen based on the treatment of specific tumors.
PROSTATE THERAPY
The first level of evidence for using HIFU to treat prostate tumors was a feasibility study conducted
FIG. 1.
Heat diffusion over an animal model after a highintensity focused ultrasound (HIFU) treatment. A mock blue vessel is diagramed to illustrate the diffusion of heat attributed to blood flow after a HIFU treatment. The numerical graduations represent time steps in seconds after insonation. This was seen with both a bovine tongue and a rabbit's ear. The diagram represents the physiologic concerns that must be considered when planning a treatment to an area of tissue and related diffusion of heat.
with 29 subjects with localized tumors. 13 This study treated 29 subjects, but only 10 were followed after HIFU therapy to surgical removal of the prostate. The methodology for providing HIFU therapy to these subjects was to gradually expose the tumor site with sonographic intensities from 1260 to 2000 W/cm 2 . A transrectal approach was used with transducers of varied focal lengths (3-4 cm). The treatments were 4 seconds of insonation followed by 12 seconds of no exposure. Some subjects were monitored for temperature changes in the surrounding tissues. The data on 6 patients demonstrated an intraprostatic temperature rise to 98.6°C (209°F). Postsurgical evaluation of the treated prostate tissue was evaluated for tissue and vascular necrosis. Pathologic evidence of the 10 cases revealed that the entire tumor was destroyed in 3, and 53% were destroyed in the other 7 specimens. This study was interesting, but the small numbers and varied technique make it difficult to translate to clinical practice.
In a similar feasibility study of 10 patients ranging from 58 to 69 years of age, HIFU was used to treat their prostate cancer.
14 This research, conducted in the Netherlands, was completed 7 to 12 days prior to surgical removal of the prostate. A 2.25-MHz transducer was used to deliver foursecond exposures to the prostate at 1000 W/cm 2 . A balloon with 18°C (64.4°F) fluid was placed around the probe to avert heating damage to the rectal wall. Pathology confirmed that nine specimens demonstrated complete destruction of the tumor on the dorsal surface. In two cases, the untreated surface of the prostate had residual tumor cells. This study was methodologically easier to replicate, but the intensity and monitoring of temperature was not as clearly defined.
A cohort study was conducted with 31 patients for the purpose of treating the prostate with HIFU and directed therapy by monitoring the flexibility of the tissue. 15 Of these patients, 29 had the entire organ insonated and monitored with MRI to combat residual tumor growth. The HIFU transducer had a 4-cm focal length with 30-W bursts given in stepwise progressions across the organ. The treatments were provided in five-second intervals with five-second rests between treatments. Color Doppler was used to measure the flexibility of the prostate tissue. Color Doppler allows for the detection of motion and depicts direction of movement with specified color and intensity. The tumor was believed to cause rigidity within the tissue; therefore, less flexibility in a suspicious area could denote a tumor. This has been professionally referred to as elastography and was the technique used in the study. Elastography was combined with the HIFU treatments. A balloon was inflated to transmit vibrations within the prostatic tissue, allowing this technique to guide HIFU treatments. The stiffness of the tissue was monitored during imaging to detect the tumor's location and the effectiveness of the treatments. Unfortunately, many of the patients did not have surgical removal of the prostate, so biopsy results had to be used to confirm the presence of the tumor. This study demonstrated the feasibility of using elastography to detect the prostate tumor as well as a method for targeting HIFU therapy.
A small Italian cohort study was initiated with 30 men diagnosed with prostate cancer. HIFU was used in addition to hormone therapy to treat the residual cells after the transurethral resection of the tumor. 16 The patients were followed for maximum of one year with prostate-specific antigen (PSA) levels and biopsies to gauge the progression of the disease within the prostate. A transurethral resection of the prostate (TURP) was performed prior to HIFU treatments with a biplane 7.5-MHz transrectal sonographic probe that provided imaging as well as therapy. The treatments were done at 3 MHz and focused at 40 mm for five seconds, followed by five seconds of rest. The treatments done were not specifically targeted; they were given across the entire gland. The prostate with residual tumor was treated in zones with some overlap in the treatments (see Fig. 2 ). Two patients in this study experienced incontinence for up to one year after the initial treatments. Due to the age of the patients (mean age 73.5 years), concerns for incontinence and impotence were disregarded.
14 The study's outcome was that all the participants monitored with PSA demonstrated values in the normal range. This study is a unique use of HIFU as a treatment of patients with posttumor resection and demonstrated a protocol for treatment across the entire organ. The protocol must be further refined because overlap could be related to changes in continence among these patients.
Longitudinal studies provided additional evidence on the use of HIFU to treat prostate tumors. The most recent is a Chinese study of 281 prostate cancer patients who were tracked for 12 months to document the effectiveness of HIFU treatments. 17 The pathological confirmation for this study was made through the use of biochemical markers. Normal PSA values were directly related with HIFU treatments over the year since treatment. The transrectal transducer used in this study was 4 MHz and delivered between 1300 and 1680 W/cm 2 of ultrasound. The therapy treatments were controlled by a computer to avoid human error. The successful lowering of PSA values after HIFU therapy was statistically significant. This study provided significant support for HIFU as a treatment option to promote the long-term health in these patients. This study was more rigorous than other studies that varied the HIFU frequency or recruited patients with advanced disease. 18, 19 These types of studies provide important information on the use of PSA as a means to monitor the outcome of HIFU therapy.
The highest level of evidence reviewed were animal experiments, which were conducted on canine prostates and treated with HIFU to induce necrosis of abnormal tissue. An early experimental study with 37 dog prostates allowed treatments to be varied from 720 to 2300 W/cm 2 with insonations lasting from one to four seconds. 20 The temperatures in these early studies went up to 85°C (185°F), so more studies were needed on methods to monitor treatment. A later study with 10 canine prostates used an amended protocol that included MRI to detect overall temperature changes in surrounding tissues during HIFU therapy. 21 Three gradient magnetic resonance images were acquired every 15 seconds, including baseline images prior to treatment. This technique was able to document the rise in tissue temperature to a maximum of 52°C (125.6°F). Concerns over tissue motion from the animals had the potential to cause a misregistration of the data. In this experiment, the magnetic resonance images proved to be very helpful in gauging the therapeutic temperature as well as the cooling process of surrounding tissues. One problem with these studies is the varied used of transducer frequencies and a consistent HIFU protocol, which would allow for replication of the technique when coupled with MRI monitoring.
The studies selected for review revealed the promise of HIFU as a noninvasive technique; however, more studies are needed. There is a need for comparative studies that involve randomized assignment of patients with prostate tumors to provide a higher level of clinical evidence. Researchers are encouraged to provide all the technical details, which include the output power, transducer frequency, length of treatment, and method of treatment to allow for proper comparison of data. Evidence thus far indicates that HIFU, for therapeutic treatment of prostate tumors, is a viable option. It may have promising impact for those patients with inoperable types of tumors or are unstable for surgical intervention.
LEIOMYOMATA THERAPY
The lowest level of evidence for HIFU ablation of leiomyomata was a study to determine a prototype HIFU device's feasibility. 22 The device was evaluated using turkey breast samples in a gel phantom and a 3.5-MHz transducer with a fixed focal length of 40 mm. The intensities that were generated by the device were above 1250 W/cm 2 . In addition to the experimental studies performed in this study, the technique was tested on six healthy volunteers to ensure that an examination could be conducted. The result of these translational investigations of HIFU to ablate fibroids was to advocate the use of a transvaginal approach.
Building on this type of research, a study was conducted with human specimens in vitro that were subjected to HIFU, as part of an experimental setup. 23 The fibroid and myometrium specimens were insonated, and the speed of sound (SOS) was measured within the target, before and after HIFU. The HIFU treatment was completed with a 3.5-MHz transducer that generated up to 2000 W/cm 2 . The treatment exposure lasted from 40 to 60 seconds. Transducers were positioned on either side of the specimen to record the SOS. The experimental result demonstrated that SOS was slightly increased in the targeted areas after HIFU. Although only three samples were tested, the in vitro experiment provided some preliminary data on the measurement of SOS as a method of monitoring the necrosis within the targeted tissue. Additional studies would need to be conducted to measure SOS as the metric for a successful HIFU therapy, especially because MRI has been the modality used to monitor the success for most patient studies.
The same team of researchers conducted an animal experiment to determine the utility of HIFU to destroy fibroid formation within the uterus. This study used 27 rats with 35 uterine fibroids to gauge the effectiveness of HIFU in causing vascular necrosis with the targeted lesions. 24 In the study, the fibroids were surgically exposed and treated with HIFU applied by a 3.5-MHz transducer that fired ten-second pulses to a depth of 10 mm. The rats were randomly divided into treatment and control groups, with the treatment being HIFU therapy. The result was that greater than 50% of the fibroids treated with HIFU demonstrated a significant decrease in volume. The control group of rats went on to demonstrate a 40-fold increase in fibroid size. This highly structured experiment had a sophisticated methodology but would require further testing to translate to human treatment.
The highest level of evidence was provided by an international cohort study staged at five different clinical sites with 55 women consenting to HIFU treatment of their fibroid tumors. 25 This study was difficult to follow as the clinical sites were not consistent with their pathologic confirmation. Some participants had a hysterectomy after their HIFU therapy, and others refused gynecologic surgery. All of the patients were exposed to 500 to 700 W/cm 2 at the targeted site and were monitored with MRI to determine the resulting tissue temperature. This study was significant in that MRI mapping demonstrated that tissue necrosis extended past the targeted area. Those patients who underwent hysterectomy provided pathologic confirmation of necrosis that extended past the treatment site. The patient's fibroids were large enough that the necrosis that extended past the fibroid did not approach the myometrium. This study was very important as it points to the need to have a method for tracking the collateral increase in heat that dissipates away from the targeted site. Necrosis is not confined to the center of the treatment but should be assumed to move out into the surrounding tissue. Targeted sites for HIFU must be carefully selected and monitored to avoid damage to normal tissue.
These studies provide encouraging results for the use of HIFU to induce necrosis of fibroid formation within the uterus. Continued human studies are needed to ensure that the technique can be standardized and that the collateral damage can be minimized. The best evidence provided that influences clinical practice would be using MRI to monitor the temperature that exceeds the central HIFU treatment site.
GLIOBLASTOMA THERAPY
Evidence-based studies on the use of HIFU to destroy glioblastomas in the brain begin with a case report of using this technique to open the blood-brain barrier (BBB). Opening the BBB allows for administration of chemotherapy agents targeting recurrent giloma tumor margins. HIFU used in this manner insonates exposed brain tissue intraoperatively, thereby applying heat to create a BBB opening for up to three days. 26 The opening of these tightly packed endothelial cells is enough to allow chemotherapy agents to attack the remnants of the tumor that has been removed. Pernot et al. 27 moved the field forward by using computed tomography (CT) images of the human skull to create a model for refining the HIFU technique. Computer software created a 3D model that allowed for a computation of the treatment dose moving through the brain and the temperature elevation. This information helped to refine the positioning of the transducer array that could be used to deliver a more focused HIFU dose. The result of this simulation was the discovery of the need to adjust each transducer to control the intensity and temperature that would result within the human brain.
A cohort study with healthy men was conducted with HIFU to alter the blood-brain barrier. Besides the use of HIFU, the participants were injected with two different sonographic contrast mediums as well as gadolinium for MRI. 28 The transducer provided an intensity of 700 mW/cm 2 , and the participants were imaged by MRI before, during, and after the treatment. Six men were injected with the first sonographic contrast agent and exposed to sonography at 3.5 MHz and the transmit power set on maximum. After four months, the second phase of the study was conducted with a different sonographic contrast agent; these participants were exposed to the same level of sonographic intensity. The use of the contrast agents and exposure to HIFU energy promoted microbubble destruction within brain tissue. MRI images were used to monitor the brain for temperature and any structural damage to the brain. This study, although small, is a human trial that proved the BBB could be opened successfully. It also demonstrated that sonographic contrast agents could be included as part of a specific drug treatment that can be delivered and activated to treat lesions in the brain.
The next level of evidence is an experiment with sheep brain tissue. The first series of HIFU experiments was done with a partial craniotomy, in order to obtain a model, to conduct the research. 29 A device was constructed with an array of 280 individual transducers to produce the ultrasonic therapy. A water bath was also provided to reduce the heat that builds on the surface of the skull and to conform to its contour. A hydrophone was implanted in the animal brain to allow for feedback to determine the amount of power needed to penetrate the skull and correspondingly reach the brain tissue. A similar experimental device was used as a prototype for creating HIFU energy and channeling it through a metal tube. 30 The use of sheep to test a prototype HIFU unit was important because the size of the head was similar to that of a human. Once the intensity was determined, the treatments were provided for 10 seconds with 15-second delays. The sheep were examined postmortem, and necrosis at the target area was confirmed. This animal experiment confirmed that ability to provide the treatment without removing bone for a HIFU treatment.
The research that has been reported for treating glioblastomas with HIFU is varied and tends to be more invasive in nature. Opening the BBB allows for invasive treatments to be conducted and could include the use of sonographic contrast bubble technology to promote cavitations within the targeted lesion. Fusion of HIFU with MRI seems to be the next frontier to allow for a more controlled therapy.
Recommendations/Conclusions
The clinical findings from this analysis of published literature, regarding the utilization of HIFU for these specific tumors, are best described as exploratory. This review was centered on the progress that has been made in determining the applicability of using HIFU to treat tumors of the prostate, uterus, and brain. The literature that was located and reviewed provided studies that build evidence for translating this technology to human treatment. This is not a new technique and actually had been originally investigated in the 1940s. 31 The technological progress and the translational information from these studies also point to a new approach for monitoring the heating and caviation effects in human tissue. Elastography with color Doppler and the use of MRI to monitor tissue changes suggest a fusion of sorts, to increase the effectiveness of HIFU in treating tumors. It has been suggested that to achieve spatially accurate treatments that are closely monitored, fusion of imaging with HIFU will need to be part of the therapy protocol. 32 Studies continue to be conducted in other areas of the human body to discern the utility of HIFU in creating vascular necrosis in tumors without causing collateral tissue damage. 33 Besides applications of HIFU with other malignancies, research is still needed in the area of focusing the sonographic beam and the technique of gradual pulsed exposures to achieve a cumulative therapy result. The continued study of HIFU holds the promise of developing a noninvasive, nonionizing treatment for certain malignancies.
